PHILADELPHIA, PA and REHOVOT, ISRAEL -- (Marketwire) -- 10/11/12 -- Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today announced that E. Robert Wassman, M.D. and Dganit Bar, Ph.D. will join the Company in the newly created positions of Chief Medical Officer and Chief Scientific Officer, respectively, as of October 22, 2012.
"We are delighted to add Drs. Wassman and Bar to our leadership team. Each brings considerable experience and insight that will be invaluable as we grow Rosetta Genomics into a leading molecular diagnostics and personalized medicine company," stated Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics.
In addition to a successful career as a medical geneticist, Dr. Wassman has more than 30 years of experience in executive roles at leading genetic testing companies including Genzyme Genetics, Alfigen/The Genetics Institute, Good Start Genetics, and Genetrix, Specialty Laboratories. Prior to joining Rosetta Genomics, Dr. Wassman was Chief Medical Officer, Executive Vice President & Chief Genomics Officer at Generation Health.
Dr. Wassman is widely published with contributions to medical books and articles in peer-reviewed journals and lay publications. He graduated cum laude from Yale University with a B.S. in Biology and earned his M.D. at Albany Medical College. He conducted his internship in pediatrics at New York Hospital-Cornell University Medical Center and was a Fellow in the Medical Genetics-Division of Medical Genetics, Department of Pediatrics at Harbor-UCLA Medical Center. Dr. Wassman served as a Clinical Assistant Professor of Pediatrics at Harbor UCLA Medical Center for many years subsequently.
Dr. Bar joins Rosetta Genomics with 12 years of experience in drug development. Most recently she was Executive Director, Science and Technology at BioLineRx, Ltd. in Jerusalem, where she supervised the company's out-licensing and partnering activities, managed alliances with U.S. partners, and evaluated new and ongoing projects from both business and scientific aspects.
From 2000 to 2004 Dr. Bar was with QBI Enterprises, Ltd., Ness-Ziona, where she was Head of Cancer Research and managed research groups working on the company's oncology pipeline. Dr. Bar led the development of early and late-stage preclinical, as well as clinical drug candidates. As Manager of the Development Team at QBI, Dr. Bar was responsible for planning and supervising efficacy studies, GLP genotox, safety pharmacology, acute- and long-term toxicity and PK studies, clinical supplies and manufacturing.
Dr. Bar received her B.Sc. in Life Science from The Hebrew University, Jerusalem. She holds a M.Sc. in Biotechnology and a Ph.D. in Biotechnology Engineering from Ben-Gurion University of the Negev.
"These new positions are critical to our growth strategy. As a leading authority on genetics, Dr. Wassman's vast experience and skillset will be a considerable asset to Rosetta as we continue to ramp up our efforts to commercialize our current, clinically focused assays and seek to bring new assays to the market. Our strengthened financials allow us to reinvigorate our development efforts, and Dr. Bar's expertise in this area will be invaluable as we work to capitalize on our powerful and versatile microRNA platform," added Mr. Berlin.
Most Popular Stories
- World Bank: Rich Countries Must Curb Emissions
- Airport Garners Social Media Award
- Social Media Campaign Increases Organ Donor Registrations
- What Will Happen When Quantitative Easing Ends?
- Immigration Reform Would Decrease U.S. Budget Deficit
- MillerCoors Taps New Hispanic Ad Agency
- Aetna Leaving California's Individual Health Insurance Market
- Conference Slated for Hispanic Tech Startups
- Tea Party Wants to 'Audit the IRS'
- Calories Count: Starbucks to Post the Numbers on Menu Boards